Table 1.

Meta-analysis of nine validated SNPs using two published melanoma GWAS datasets

				The MDACC Study (n = 858)					The Harvard Study (n = 409)			Meta-analysis
SNP	Allelea	Gene	Chr	EAF	HR (95% CI)b	P b	FDR	FPRP	EAF	HR (95% CI)c	P c	P het	I 2	HR (95% CI)d	P d
rs485412	T/C	CHRM3	1q43	0.24	0.66 (0.46–0.95)	0.026	0.533	0.200	0.25	0.57 (0.33–0.97)	0.039	0.660	0.000	0.63 (0.47–0.85)	2.90 × 10−3
rs1104370	A/G	CHRM3	1q43	0.24	0.66 (0.46–0.95)	0.026	0.533	0.200	0.25	0.57 (0.33–0.97)	0.039	0.660	0.000	0.63 (0.47–0.85)	2.90 × 10−3
rs2841038	G/T	CHRM3	1q43	0.24	0.65 (0.45–0.94)	0.024	0.513	0.187	0.26	0.56 (0.33–0.96)	0.036	0.650	0.000	0.62 (0.46–0.84)	2.10 × 10−3
rs2623439e	A/G	PDE1A	2q32.1	0.30	1.44 (1.06–1.95)	0.020	0.479	0.154	0.28	1.51 (1.01–2.28)	0.047	0.860	0.000	1.46 (1.15–1.87)	2.22 × 10−3
rs1430157	C/T	PDE1A	2q32.1	0.31	1.41 (1.04–1.90)	0.026	0.530	0.188	0.29	1.61 (1.07–2.41)	0.016	0.610	0.000	1.48 (1.16–1.88)	1.52 × 10−3
rs6750552	T/C	PDE1A	2q32.1	0.33	1.47 (1.08–1.98)	0.013	0.446	0.106	0.30	1.62 (1.07–2.45)	0.021	0.710	0.000	1.52 (1.19–1.94)	7.21 × 10−4
rs10931014	T/C	PDE1A	2q32.1	0.33	1.39 (1.04–1.87)	0.027	0.535	0.200	0.30	1.65 (1.09–2.49)	0.018	0.510	0.000	1.47 (1.16–1.87)	1.59 × 10−3
rs6785564	A/G	ITPR1	3p26.1	0.14	0.51 (0.32–0.81)	0.004	0.382	0.062	0.14	0.44 (0.20–0.96)	0.040	0.750	0.000	0.49 (0.33–0.73)	3.94 × 10−4
rs2596191	C/A	RYR3	15q13.3-q14	0.44	0.69 (0.51–0.93)	0.016	0.460	0.130	0.42	0.64 (0.41–0.98)	0.039	0.780	0.000	0.67 (0.53–0.86)	1.71 × 10−3

EAF, effect allele frequency; FDR: false discovery rate; FPRP: false-positive report probability; P_het, P value for heterogeneity by Cochrane’s Q test.

^aReference allele/effect allele.

^bAdjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in the MDACC study.

^cAdjusted for age and sex in the Harvard study.

^dMeta-analysis in a fix-effects model.

^eSNP genotyped, or else SNP imputed.